A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)

Inclusion Criteria:

• Patients, as defined by local regulations and local faricimab product label, who areinitiating treatment with faricimab at time of enrollment or have initiatedtreatment with faricimab within 3 months prior to patient enrollment, in diabeticmacular edema (DME) or neovascular age-related macular degeneration (nAMD) in atleast one eye according to the investigator's discretion in routine clinicalpractice for anti-VEGF treatment naïve and pre-treated patients.

• Patients have received at least one faricimab treatment (the first dose) in thestudy eye.

Exclusion Criteria:

• Concomitant participation of the patient in any investigational ophthalmologyclinical trial that includes receipt of any ophthalmological investigational drug orprocedure within the last 28 days prior to enrollment

• Current participation in any interventional clinical study

• Active ocular inflammation and/or suspected/active ocular infection in either eye

• Patients in whom the study eye has been treated with faricimab for more than 3months prior to enrollment

• Patients treated with faricimab who have and are currently participating in patientsupport programs (PSP) that are Market Research and Patient Support Programs (MAP)including Post Trial Access Programs (PTAP) and Compassionate Use Programs (CUP)

• Patients with non-ocular sight threatening disease which have an effect on theprimary endpoint (e.g., apoplexia)

• Hypersensitivity to the active substance or any of the excipients of Vabysmo (as perlabel)